Transapical Transcatheter Aortic Valve Implantation Using the JenaValve: A One-Year Follow-up

Abstract

Objective Since the first transcatheter aortic valve implantation (TAVI) in 2002, TAVI technique has gained an increasing popularity especially in high-risk patients. In this study, we present the first echocardiographic midterm outcome with the second-generation transapical JenaValve TAVI system (JenaValve Technology GmbH, Munich, Germany) in patients with aortic stenosis (AS).

Methods Between November 2011 and November 2012, a total of 28 patients received transapical TAVI using the JenaValve. Primary endpoint was a combined efficacy endpoint after 1 year, which included all-cause mortality after more than 30 days, failure of current therapy for AS requiring hospitalization for symptoms of valve-related cardiac decompensation or prosthetic heart valve dysfunction. Moreover, we analyzed secondary endpoints after 3 and 12 months including cardiovascular mortality; major stroke; and life-threatening, disabling, or major bleeding. Mean echocardiographic follow-up was 471.35 ± 102.72 days.

Results Mean age was 80.43 ± 6.03 years and EuroSCORE II was 8.80 ± 7.21%. Successful implantation was accomplished in 100% (n = 28). Median transvalvular aortic mean pressure gradient was 44.5 mm Hg (interquartile range [IQR]: 34.5; 55.5) preoperatively, 12 mm Hg (IQR: 9; 16) postoperatively, and 11 mm Hg (IQR: 8; 16) after 1 year. After 12 months, no paravalvular leakage was seen in 52.38% of the patients and grade 1 paravalvular leakage was seen in 47.62% of the patients. There was no grade 2 or 3 leakage detected. Stroke, valve thrombosis or dislocation, myocardial infarction, or bleeding was also not observed. However, criteria for the combined efficacy endpoint after 1 year were met in five patients (17.86%). Thirty-day mortality was 14.29% (n = 4) and all-cause mortality after 1 year was 21.43% (n = 6).

Conclusion The JenaValve transapical TAVI system is a safe and feasible procedure with low peri- and postoperative complications and convincing midterm performance of the prosthesis.

Keywords

aortic valve and root - heart valve - transapical - TAVI - outcomes

• References

• 1 Cribier A, Eltchaninoff H, Bash A , et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106 (24) 3006-3008
• 2 Leon MB, Smith CR, Mack M , et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363 (17) 1597-1607
• 3 Sinning JM, Hammerstingl C, Vasa-Nicotera M , et al. Aortic regurgitation index defines severity of peri-prosthetic regurgitation and predicts outcome in patients after transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 59 (13) 1134-1141
• 4 Reuthebuch O, Inderbitzin DT, Rüter F , et al. Single-center experience and short-term outcome with the JenaValve: a second-generation transapical transcatheter aortic valve implantation device. Innovations (Phila) 2014; 9 (5) 368-374 , discussion 374
• 5 Kappetein AP, Head SJ, Généreux P , et al; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg 2013; 145 (1) 6-23
• 6 Vahanian A, Alfieri O, Andreotti F , et al; ESC Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012; 42 (4) S1-S44
• 7 Lefèvre T, Kappetein AP, Wolner E , et al; PARTNER EU Investigator Group. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur Heart J 2011; 32 (2) 148-157
• 8 Walther T, Simon P, Dewey T , et al. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 2007; 116 (11, Suppl): I240-I245
• 9 Seiffert M, Conradi L, Kloth B , et al. Single-centre experience with next-generation devices for transapical aortic valve implantation. Eur J Cardiothorac Surg 2015; 47 (1) 39-45
• 10 Ensminger S. JenaValve's Transapical TAVI System: Most Up to Date Clinical Results. Presented on euroPCR 2014 in Paris
• 11 Abdel-Wahab M, Zahn R, Horack M , et al; German transcatheter aortic valve interventions registry investigators. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart 2011; 97 (11) 899-906
• 12 Kodali SK, Williams MR, Smith CR , et al; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366 (18) 1686-1695
• 13 Tamburino C, Capodanno D, Ramondo A , et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011; 123 (3) 299-308
• 14 Ensminger S, Utzenrath M, Kütting M , et al. Eccentricity of the aortic annulus is not associated with functional impairment of the transapical Jenavalve in an in vitro hydrodynamic test model. Thorac Cardiovasc Surg 2014; ; 62-SC200 (cited December 16, 2014). Available at: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0034-1367461